tunlametinib
Phase 3Small molecule
tunlametinib is one of 90 small molecule programs targeting Melanoma Metastatic. It is currently in Phase 3.
3
Indications
5
Total Trials
5
Active Trials
89
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
191 competitors in Melanoma
#DrugCompanyPhaseTrials
1Mekinist
NovartisPhase 3
Keytruda
Merck & Co.Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Cotellic
RochePhase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Phase 3
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Taxol
TevaPhase 3
Mektovi
PfizerPhase 3
Tecentriq
RochePhase 3
Proleukin
IIovance Biotherapeutics, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Melanoma3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for tunlametinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SShanghai Kechow Pharma, Inc.